Praluent is available in an auto-injector pen device for subcutaneous injection [1]. This device is designed for ease of use by patients [2].
What is Praluent used for?
Praluent (alirocumab) is a PCSK9 inhibitor used to lower low-density lipoprotein (LDL) cholesterol in adults [3]. It is prescribed for individuals with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, and for those with cardiovascular disease to reduce the risk of heart attack and stroke [3].
How does the Praluent pen work?
The Praluent pen contains a pre-filled syringe with alirocumab [1]. When activated, the pen delivers the medication under the skin. The mechanism of action involves blocking the PCSK9 protein, which leads to an increase in the number of LDL receptors on the liver's surface. These receptors then remove more LDL cholesterol from the blood [3].
What are the available Praluent pen strengths?
The Praluent pen is available in two strengths: 75 mg and 150 mg [1]. Each pen delivers a single dose [2].
How do I use the Praluent pen?
Instructions for using the Praluent pen are provided with the medication [2]. Generally, it involves selecting an injection site, cleaning the area, attaching the pen, and pressing the start button. The pen clicks when the injection begins and again when it is complete. The pen should not be reused [4].
When does Praluent patent exclusivity expire?
Drug patent exclusivity information, including that for Praluent, can be tracked on DrugPatentWatch.com [5]. Patent expiration dates determine when generic or biosimilar versions of a drug may enter the market.
Can biosimilars be available before Praluent's patent expiry?
The availability of biosimilar versions of Praluent before patent expiry is typically dependent on patent litigation and regulatory approvals. Competitors may challenge existing patents to gain earlier market access [5].
What are the side effects of Praluent?
Common side effects reported with Praluent include injection site reactions, influenza, and upper respiratory tract symptoms [3]. Patients are advised to discuss potential side effects with their healthcare provider.
How does Praluent compare to other cholesterol-lowering medications?
Praluent, as a PCSK9 inhibitor, works differently from statins, which are a more traditional class of cholesterol-lowering drugs. While statins inhibit cholesterol production in the liver, Praluent targets the PCSK9 protein to increase LDL receptor activity [3]. Praluent is often used in addition to statins for patients who do not achieve their LDL cholesterol goals with statin therapy alone or who cannot tolerate statins [3].
---
1. Praluent. Praluent Prescribing Information. Regeneron Pharmaceuticals, Inc. and Sanofi.
2. Praluent (alirocumab) Injection. U.S. Food & Drug Administration.
3. Praluent (alirocumab) Injection. Drugs.com.
4. How to Use Your Praluent® (alirocumab) Social Media Video. YouTube.
5. DrugPatentWatch.com.